Seres Therapeutics (MCRB) Misses Q4 EPS by 61c

Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Sprinklr Inc (CXM) PT Raised to $7.50 at Cantor Fitzgerald
• Curl Warehouse Launches Canada's First Curl Hair Index for Curly Hair